Is JNJ still a good investment?
Johnson & Johnson isn't the safe stock it used to be
Should I invest in JNJ now?
Johnson & Johnson's analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
Will Johnson and Johnson stock recover?
We estimate Johnson & Johnson's Valuation to be $180 per share, reflecting over 15% upside from its current levels of $152. Our forecast is based on a 17x P/E multiple for JNJ and expected earnings of $10.70 on a per-share and adjusted basis for the full year 2024.
Is Johnson and Johnson a long-term investment?
The company's financials may not be as strong in the future
In 2023, Stelara generated $10.9 billion in revenue. Between 2025 and 2030, Johnson & Johnson projects that it will generate annual growth between 5% and 7%, hoping the development of new drugs to will help offset the loss of exclusivity for Stelara.
What is the long-term outlook for JNJ?
In December, the company announced its long-term guidance, which projected an annual growth rate between 5% and 7% from 2025 through to 2030.
Is Johnson and Johnson a risky investment?
Johnson & Johnson isn't the safe stock it used to be
Until there is a resolution to the talc-related issues, the stock is simply too big of a risk these days. The legal bills pose a threat to the company's dividend and its long-term growth objectives.
What will happen to JNJ shares?
What happens to JNJ stock when the company splits? Once Johnson and Johnson splits, JNJ stock will only give traders and investors exposure to the medical device and pharmaceutical proceeds of the company. The new company, which will be listed as Kenvue, will trade separately.
What are analysts saying about JNJ stock?
Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $174.8 with a high estimate of $215 and a low estimate of $155.
Is JNJ stock recession proof?
With decades of dividend increases and a strong and diversified business model, Johnson & Johnson (NYSE:JNJ) ranks seventh in our list of the best stocks to buy before recessions.
Why are JNJ shares falling?
Johnson & Johnson (JNJ) stock skidded early Tuesday after light sales of blockbuster psoriasis treatment Stelara dragged the company's top line lower. Stelara sales were flat at $2.45 billion, but came in 5% below expectations, Leerink Partners analyst David Risinger said in a report.
Which is better to invest in Pfizer or Johnson and Johnson?
PFE's forward EV/Sales multiple of 2.94 is lower than JNJ's 4.35. PFE's forward EV/EBITDA multiple of 8.78x is lower than JNJ's 12.07x. PFE's trailing-12-month levered FCF margin of 8.29% is lower than JNJ's 23.23%. In addition, PFE's trailing-12-month asset turnover ratio of 0.33x is lower than JNJ's 0.48x.
What will JNJ stock be worth in 5 years?
Johnson & Johnson stock price stood at $149.12
According to the latest long-term forecast, Johnson & Johnson price will hit $150 by the middle of 2024 and then $200 by the end of 2027. Johnson & Johnson will rise to $250 within the year of 2029 and $300 in 2032.
Who is the biggest investor in Johnson and Johnson?
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VFINX - Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Spdr S&p 500 Etf Trust, and ...
What is the future of Johnson and Johnson?
J&J expects to grow operational sales by 5%-7% through 2027. Notably, it anticipates a third of its sales to come from new products in 2027. The company set 2024 sales growth forecasts for between 5%-6%. It expects adjusted earnings per share to range between $10.55 and $10.75.
What will JNJ stock price be in 2024?
| Date | Open | High |
|---|---|---|
| Apr 23, 2024 | 149.86 | 150.49 |
| Apr 22, 2024 | 148.51 | 150.27 |
| Apr 19, 2024 | 146.15 | 148.13 |
| Apr 18, 2024 | 144.98 | 145.80 |
How many times a year does JNJ pay dividends?
Johnson & Johnson ( JNJ ) pays dividends on a quarterly basis. Johnson & Johnson ( JNJ ) has increased its dividends for 52 consecutive years. This is a positive sign of the company's financial stability and its ability to pay consistent dividends in the future.
Is JNJ a buy or sell?
Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 43 buy ratings, 32 hold ratings, and 1 sell ratings.
What is the cash on hand for JNJ?
Cash on Hand as of December 2023 : $22.92 B
According to Johnson & Johnson's latest financial reports the company has $22.92 B in cash and cash equivalents.
Can I invest in Johnson and Johnson?
Can I buy stock directly from Johnson & Johnson? Johnson & Johnson does not have a direct purchase program available to the general public. However, existing shareowners may make additional purchases of stock without fees or commissions through the Johnson & Johnson Dividend Reinvestment Program (DRIP).
Is JNJ in trouble?
J&J now faces at least 51,000 lawsuits claiming talc used in baby power and similar products caused cancer. Johnson & Johnson said it is weighing a third attempt to use bankruptcy for an $8.9 billion settlement of tens of thousands of lawsuits that allege tainted talc in the company's baby powder caused cancer.
Who owns the most JNJ stock?
According to the latest TipRanks data, approximately 61.13% of Johnson & Johnson (JNJ) stock is held by retail investors. Vanguard owns the most shares of Johnson & Johnson (JNJ).
Is JNJ going to split into two companies?
Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. Johnson & Johnson is peeling off a consumer health business that helped it become the world's biggest health care products maker.
Is Johnson and Johnson stock undervalued?
The intrinsic value of one JNJ stock under the Base Case scenario is 156.07 USD. Compared to the current market price of 150.08 USD, Johnson & Johnson is Undervalued by 4%. What is intrinsic value? Johnson & Johnson's market capitalization is 361.3B USD.
Is Coca Cola a buy or sell?
Is Coca-Cola stock a Buy, Sell or Hold? Coca-Cola stock has received a consensus rating of buy. The average rating score is A1 and is based on 38 buy ratings, 9 hold ratings, and 0 sell ratings.
How high is Apple stock expected to go?
Apple Stock Forecast
The 30 analysts with 12-month price forecasts for Apple stock have an average target of 204.6, with a low estimate of 158 and a high estimate of 250. The average target predicts an increase of 21.70% from the current stock price of 168.13.
